期刊
INTERNATIONAL JOURNAL OF CANCER
卷 139, 期 10, 页码 2336-2342出版社
WILEY
DOI: 10.1002/ijc.30276
关键词
ado-trastuzumab emtansine; T-DM1; biomarkers; metastatic breast cancer; HER2
类别
资金
- Novartis
- Genentech, Inc.
In the phase III TH3RESA study (NCT01419197), 602 patients with HER2-positive advanced breast cancer who received prior taxane therapy and >= 2 HER2-directed regimens, including trastuzumab and lapatinib (advanced setting), were randomized to trastuzumab emtansine (T-DM1) or treatment of physician's choice (TPC). A statistically significant progression-free survival (PFS) benefit favoring T-DM1 was demonstrated. Here, we examine the relationship between HER2-related biomarkers and PFS in an exploratory analysis. Biomarkers assessed included HER2 (n=505) and HER3 (n=505) mRNA expression, PIK3CA mutation status (n=410) and PTEN protein expression (n=358). For biomarkers with continuous data (HER2, HER3, PTEN), subgroups were defined using median values (>median and <= median). For all biomarker subgroups, median PFS was longer with T-DM1 vs. TPC. The PFS benefit favoring T-DM1 vs. TPC was numerically greater in the HER2 mRNA >median subgroup (7.2 vs. 3.4 months; unstratified hazard ratio [HR], 0.40; 95% CI, 0.28-0.59; p < 0.0001) vs. <= median subgroup (5.5 vs. 3.9 months; HR, 0.68; 95% CI, 0.49-0.92; p=0.0131). The PFS benefit with T-DM1 was similar among HER3, PIK3CA and PTEN subgroups. Consistent with other reports, benefit was seen with T-DM1 regardless of PIK3CA mutation status. In a multivariate analysis including an interaction term (treatment group by log2-transformed HER2 mRNA), patients with higher HER2 mRNA levels benefited more from receiving T-DM1 (HR, 0.84; 95% CI, 0.75-0.94; interaction p value=0.0027). In summary, T-DM1 prolonged median PFS in all biomarker subgroups analyzed, including activating PIK3CA mutations, with numerically greater benefit in patients with tumors expressing HER2 mRNA > median vs. <= median.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据